Difference between revisions of "CH391L/S13/Probiotics"

From OpenWetWare
Jump to: navigation, search
Line 4: Line 4:
==Probiotics: Why we care. ==
==Probiotics: Why we care. ==
To understand the reason why we care about probiotics, at how we gained our current understanding of the microbiota and the relation that exists mainly by studying the gut microbiota.
'''=== Gut microbiome and its benefits ===='''
== Use of Probiotics in Healthcare: Current and Future Approaches ==
*The gut flora can be seen as a collection of bacteria<cite></cite> This currently has been expanded to include also archea, fungi, and viruses.
*The gut microbiome is described as a complex system of microbe-microbe and host-microbe interactions that exist in stable populations.
*The advent of antiomicrobials and antibiotics that cause dysbiosis <cite></cite> and leads to observation of "bacterial barrier" that prevents other microorganisms to colonize the gut. 
== Use of Probiotics: Present and Future==

Revision as of 22:20, 17 March 2013


A probiotic (from the Latin, pro-, "in favor, for" and the Greek , biōtikós, "pertaining to life")refers to live microorganism that provides a benefit to the host, either directly or indirectly, by via interactions with the hosts cells or the host's microbiota. Such microorganism will interact by producing bioactives, biological compounds and macromolecules, that will produce such benefit.Although the concept of a probiotic has evolved since the the last century and the the first years of the current century that it acquired the current definition and we can see the health benefits humans can gain from he understanding of such interactions. Some research currently ongoing include the Human Microbiome Project[], and the use on single organisms to prevent disease. For example, the use of fecal transplantation for antibiotic-associated diarrea[].

Probiotics: Why we care.

Use of Probiotics in Healthcare: Current and Future Approaches

Oversight of Probiotics

iGEM 2009: Stanford's Approach to Probiotics

The 2009 Stanford iGEM Team project centered on probiotics and Inflammatory Bowel Disease (IBD). IBD, as explained, is caused by an imbalance of two types of T-cells, Treg cells that immunosuppres the Th17 cells that cause the inflammation seen in patients. They suggest that an novel theraputic mechanism can be achieved by in vivo regulation of these cells. Their approach focuses in constructing two different Escherichia coli(E.coli) strains, each that would contain a distinct input/output cassette , each that is referred as a device. The first device would detect as input Nitric Oxide(NO), a byproduct of inflammation and Th17 proliferation, produces retinoic acid, that blocks further CD4+ T-cells differentiation into Th17 cells. The second device detects 5-Methyl tryptophan (5MT) as an input and produces Interleukin-6 to regulate Treg proliferation to regulate their immunosuppression response. Ideally depending on the balance between these two markers, if too much NO is sensed by Device 1 it would prevent inflammation. The opposite would also be true if the second device sences to much 5MT that would immunosuppress Th17 cell by blocking their differentiation.


Probiotics and the Media links

The Media perspective on Probiotics


  1. Romero PA and Arnold FH. Exploring protein fitness landscapes by directed evolution. Nat Rev Mol Cell Bio, 2009. [Romero2009]
  2. Crameri A, Whitehorn EA, Tate E, Stemmer WP. Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol, 1996. [Stemmer1995]
  3. Giver L, Gershenson A, Freskgard PO, Arnold FH. Directed evolution of a thermostable esterase. Proc Natl Acad Sci USA, 1998. [Giver1998]
  4. Cadwell RC and Joyce GF. Randomization of genes by PCR mutagenesis. Genome Res, 1992. [Cadwell1992]
  5. Abou-Nader M and Benedik MJ. Rapid generation of random mutant libraries. Bioeng Bugs, 2010. [Abou-Nader2010]
  6. Stemmer WP. Rapid evolution of a protein by in vitro DNA shuffling. Nature, 1994. [Stemmer1994]
  7. Lin H and Cornish VW. Screening and selection methods for large-scale analysis of protein function. [Lin2002]
  8. Leemhuis H, Kelly RM, Dijkhuizen L. Directed evolution of enzymes: library screening strategies. IUBMB Life, 2009. [Leemhuis2009]